CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

Malignant Tumors Clinical Trial

Official title: Clinical Application of Chimeric Antigen Receptor Modified γδ T Cells（CAR - γ δ T Cells） in Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

Status Recruiting

Clinical Trial Summary

This is a study on the clinical application of chimeric antigen receptor modified γδ T cells (CAR - γδ T cells) in relapsed and refractory CD7 Positive T cell-derived malignant tumors.The main purpose of this study was to evaluate the efficacy of car - γ δ T cell infusion in patients with relapsed and refractory CD7 Positive T cell-derived malignancies.

Clinical Trial Description

γδT cells are known as "a great candidate for car-t cells". Although they only account for 2% - 5% of all T cells in our body, they are a natural killer. CD7 is recognized as a sensitive marker of T-ALL, and its expression level on T-ALL cells is opposite to CD3: compared with normal T cells, the expression level of CD7 on T-ALL cells is significantly increased (P < 0.001), while the expression level of CD3 on T-ALL cells is significantly decreased (P < 0.001). At the same time, CD7 expression is absent in about 10% of normal T cells, and these CD7 negative T cells have the ability of normal T cells to express cytokines. Therefore, CD7 has become a potential target for the treatment of T-ALL because of its specificity and safety. ;

Related Conditions & MeSH terms

• CAR
• Malignant Tumors
• Neoplasms

• NCT number: NCT04702841
• Study type: Interventional
• Source: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
• Contact: Xingbing Wang
• Phone: 13856007984
• Email: wangxingbing@ustc.edu.cn
• Status: Recruiting
• Phase: Early Phase 1
• Start date: June 3, 2020
• Completion date: December 2022